Cytochrome P450 102A2 Catalyzes Efficient Oxidation of Sodium Dodecyl Sulphate: A Molecular Tool for Remediation by Axarli, Irene et al.
SAGE-Hindawi Access to Research
Enzyme Research
Volume 2010, Article ID 125429, 7 pages
doi:10.4061/2010/125429
Research Article
CytochromeP450 102A2 Catalyzes EfﬁcientOxidation of
SodiumDodecylSulphate: AMolecular ToolforRemediation
IreneAxarli,AriadnePrigipaki,andNikolaos E. Labrou
Laboratory of Enzyme Technology, Department of Agricultural Biotechnology, Agricultural University of Athens, Iera Odos 75,
11855 Athens, Greece
Correspondence should be addressed to Nikolaos E. Labrou, lambrou@aua.gr
Received 5 January 2010; Revised 11 April 2010; Accepted 21 May 2010
Academic Editor: Munishwar Nath Gupta
Copyright © 2010 Irene Axarli et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Bacterial cytochrome P450s (CYPs) constitute an important family of monooxygenase enzymes that carry out essential roles in the
metabolism of endogenous compounds and foreign chemicals. In the present work we report the characterization of CYP102A2
from B. subtilis with a focus on its substrate speciﬁcity. CYP102A2 is more active in oxidation of sodium dodecyl sulphate (SDS)
than any other characterized CYP. The eﬀect of SDS and NADPH concentration on reaction rate showed nonhyperbolic and
hyperbolic dependence, respectively. The enzyme was found to exhibit a bell-shaped curve for plots of activity versus pH, over pH
values 5.9–8.5. The rate of SDS oxidation reached the maximum value approximately at pH 7.2 and the pH transition observed
controlled by two pKas in the acidic (pKa = 6.7±0.08) and basic (pKa = 7.3±0.06) pH range. The results are discussed in relation
to the future biotechnology applications of CYPs.
1.Introduction
Cytochrome P450 monooxygenases (CYPs) play a key role
in primary and secondary metabolic pathways and in drug
detoxiﬁcation. CYPs are heme-thiolate proteins which are
widely distributed in animals, plants, and microorganisms
[1, 2]. They catalyze the oxidation of nonactivated C–
H bonds, often in a regio- and stereoselective manner,
according to the equation:
RH+O2
2H+
− − →
2e− ROH + H2O. (1)
Among the members of the cytochrome P450 family, the
monooxygenase from Bacillus megaterium (CYP102A1 or
P450 BM3), it is well characterised. This protein is self-
suﬃcient monooxygenase composed of an N-terminal heme
monooxygenase linked to the C-terminal diﬂavin reductase
domain on a single polypeptide chain [1, 3–6]. The X-
ray structure of the monooxygenase domain of CYP102A1
was ﬁrst solved in 1993 [5]. Since then, several structures
of CYP102A1 mutants with and without bound substrates
[6] and one including the FMN binding domain [7]h a v e
been solved. More recently, a fragment containing the FAD
binding site was crystallized and its structure was resolved by
X-ray analysis [8].
Thegenomesequenceofthegram-positive modelorgan-
ism Bacillus subtilis 168 encodes eight cytochromes P450 [9].
Of these B. subtilis P450s, four have been wellcharacterized
at the enzyme level. For example, BioI (CYP107H1) is
involved in the early stages of synthesis of the vitamin
biotin [10]. CYP152A1 catalyzes hydrogen peroxide depen-
dent hydroxylation of long-chain fatty acids [11]. The two
other P450 monooxygenases CYP102A2 (accession number
O08394) and CYP102A3 (accession number O08336) within
the Bacillus subtilis genome that shows high similarity to
the Bacillus megaterium have been recently identiﬁed and
characterised [12–14].
Because of their broad substrate speciﬁcity and catalytic
diversity, there is an increasing interest to use P450s in
biotechnology [14–21]. The products of these enzymes
(e.g., enantiomerically pure hydroxylated or epoxidised fatty
acids and their derivatives) might ﬁnd applications in the
preparation of ﬁne chemicals for the synthesis of polymers,
ﬂavours, fragrances, for the production of pharmaceuticals,
or the optimization of lead compounds and existing drugs.2 Enzyme Research
In the present work we report the characterization of
CYP102A2 from Bacillus subtilis with a focus on its ability to
catalyze the eﬃcient oxidation of sodium dodecyl sulphate.
2.MaterialsandMethods
2.1. Materials. The pCR T7/CT-TOPO TA Expression Kit
was purchased from Invitrogen (USA). NADPH (tetra-
sodium salt, ca. 95 %), sodium dodecyl sulfate (SDS), lauric
acid, all other organic substrates and crystalline bovine
serum albumin (BSA) (fraction V) were obtained from
Sigma-Aldrich Co. (USA).
2.2. Methods
2.2.1. Cloning, Expression, and Puriﬁcationof CYP102A2 from
E. coli BL21 (DE3) Cells. B. subtilis (ATCC 168) was grown
at 30
◦C in a medium containing 1% peptone, 0.5% yeast
extract, and 1% NaCl. After 24h, cells were pelleted by
centrifugation and genomic DNA was isolated according
to a standard procedure [22]. PCR was used to amplify
the full-length gene CYP102A2 from genomic DNA using
the oligo primers synthesised to the 5  region of the gene
from the ATG start codon (5 -ATGAAGGAAACAAGC-
CCGATTCCTCAGCCG-3 ) and to the 3  end of the gene
ﬁnishing at the CTA stop codon (5 -TTTAGATCTCTA-
TATCCCTGCCCAGACATG- 3 ). The PCR reaction was
carried out in a total volume of 50μL contained 0.1μM
of each primer, 5ng template genomic DNA, 200μMo f
each dNTP, 5μL1 0× Pfu buﬀer, and 2.1 units of Pfu DNA
polymerase (Promega). The PCR procedure comprised 33
cycles of 2 minutes at 96
◦C, 2 minutes at 55
◦C, and 6
minutes at 72
◦C. A ﬁnal extension time at 72
◦Cf o r2 0
minutes was performed after the 33 cycles. The resulting
PCR amplicon was TOPO ligated into a T7 expression vector
(pCR T7/CT-TOPO). The resulting expression construct
(pCYP102A2) was sequenced along both strands and was
used to transform competent BL21(DE3) E. coli cells. E.
coli cells, harboring plasmid pCYP102A2, were grown at
37
◦C in 1L LB medium containing 100μg/mL ampicillin.
The synthesis of CYP102A2 was induced by the addition
of 1mM IPTG when the absorbance at 600nm was 0.5–
0.6. Four hours after induction, cells (approx. 3g) were
harvested by centrifugation at 8000r.p.m. and 4◦Cf o r
20min. CYP102A2 was puriﬁed by a method similar to
that described elsewhere [23]. Protein purity was judged by
SDS-PAGE. The enzyme was also cloned as a 6His-tagged
protein using the same expression vector (pCR T7/CT-
TOPO) and employing as 5  and 3  end speciﬁc primers
the sequences: (5 -ATGAAGGAAACAAGCCCGATTCCT-
CAGCCG-3 )a n d( 5  -TTTAGATCTCTATATCCCTGC-
CCAGAC-3 ). The 6His-tagged enzyme was puriﬁed using
NTA-Sepharose column according to the standard protocol.
ProteinpuritywasjudgedbySDS-PAGE.Kineticcomparison
(results not shown) of the tagged and untagged enzyme
showed that the extra 6His residues on the C-terminus
did not interfere with the activity and function of the
enzyme.
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Figure 1: The eﬀect of pH on Vmax of the CYP102A2 SDS/NADPH
reaction. Steady-state kinetic measurements were performed in
0.1M potassium phosphate buﬀers adjusted to diﬀerent pH values
(5.9–8.5).
2.2.2. Assay of Enzyme Activity, Protein and Steady-State
Kinetic Analysis. Enzyme activities were measured by deter-
mining the rate of NADPH conversion to NADP+ and
following the decrease of absorbance at 340nm. The ﬁnal
assay volume of 1mL contained 0.1M potassium phosphate
buﬀer, pH 7.2; 0.1mM NADPH; 1.735mM SDS and sample
containing enzyme activity. One unit of enzyme activity
is deﬁned as the amount of enzyme that catalyses the
conversion of 1μmol NADPH to NADP+per minute at
37
◦C. Protein concentration was determined at 25
◦C by the
method of Bradford using bovine serum albumin (fraction
V) as standard [24].
Steady-state kinetic measurements were performed at
37
◦Cin0.1Mpotassiumphosphatebuﬀer,pH7.2byvarying
the concentration of the substrates (NADPH, SDS). Initial
velocities were determined in the presence of 1.735mM SDS,
while the NADPH concentration range was 6.6–100μM.
Michaelis-Menten kinetics was observed under these inves-
tigated conditions. The kinetic parameters kcat and Km were
calculated by nonlinear regression analysis of experimental
steady-state data. Turnover numbers were calculated on the
basis of active site per 119kDa. Kinetic data were analyzed
using the computer program GraFit (Erithacus Software
Ltd.) [27]. When NADPH was used at a ﬁxed concentration
(0.1mM), the SDS varied in the range of 0.34–1.73mM.
In this case the data are best ﬁtted to the Hill function
since the curves are nonhyperbolic (sigmoidal curves). For
each experimental velocity curve, the Vmax value, S0.5 (S0.5 is
the substrate concentration at which v = 0.5Vmax), and the
Hill coeﬃcient, nH, were determined by ﬁtting the plotted
v versus substrate concentration to the Hill equation:
v =
Vmax[s]
nH
S
nH
0.5 +[s]
nH . (2)
Curve-ﬁts were obtained using the GraFit (Erithacus Soft-
ware, Ltd.) computer program.Enzyme Research 3
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Figure 2: Kinetic analysis of CYP102A2 in 0.1M potassium phosphate buﬀer, pH 7.2. (a) Initial velocity analysis with NADPH as variable
substrate (6.6–100μM) and SDS at saturation concentration. (b) Initial velocity analysis with SDS as variable substrate (0.34–1.73 mM) and
NADPH at saturation concentration. The plot of rate versus SDS concentration is nonhyperbolic and is ﬁtted to the Hill function.
2.2.3. Diﬀerence Spectroscopy. Diﬀerence spectral titrations
were performed in a Perkin-Elmer Lamda16 double
beam double monochromator UV-VIS spectrophotometer.
Enzyme solution (0.8mL; 0.077mg enzyme in 20mM
potassium phosphate, pH 7.4) and enzyme solvent (0.8mL;
20mM potassium phosphate, pH 7.4) were placed in the
sample and reference black-wall silica cuvettes (10mm path-
length), respectively, and the baseline diﬀerence spectrum
was recorded in the range 500–360nm. Identical volumes of
sodium dodecyl sulfate (SDS) solution were added to both
cuvettes and the diﬀerence spectra were recorded after each
addition.
2.2.4. pH Dependence of Vmax. The pH proﬁle of CYP102A2
was conducted at 37
◦C in 0.1M potassium phosphate buﬀer
(pH 5.9–8.5). pKa values were estimated by ﬁtting the
experimental data to the equation reported by Blanchard
and Cleland 1980 [28], using the computer program GraFit
(Erithacus Software Ltd.).
2.2.5. Bioinformatics Analysis and Molecular Modelling. A
molecular model of the heme domain of CYP102A2
was constructed using SWISS-MODEL (http://www.expasy
.org/swissmod)[ 29], as described in Axarli et al., 2005 [12].
Atomic contacts in the complex CYP102A2-palmitoleic acid
were analyzed by iMolTalk (http://i.moltalk.org/) [30] using
a distance threshold set to 4 Angstroms.
3. Results andDiscussion
3.1. Eﬀe c to fp Ho nV max for the SDS Oxidation Reaction.
P450 monooxygenases catalyze a broad range of reactions,
with diﬀerent members of the family exhibiting quite varied
substrate speciﬁcity [12, 23] .T h ee n z y m ei sm o r ea c t i v e
in oxidation of SDS than any other characterized P450
monooxygenase and therefore detailed kinetic analysis was
carried out using SDS and NADPH as substrates.
The eﬀect of pH on the Vmax for the SDS oxidation
reaction was investigated and the results are shown in
Figure 1. CYP102A2 remained catalytically active in a broad
pH range. The rate of SDS oxidation reached the maximum
value approximately at pH 7.2 (0.1M potassium phosphate
buﬀer). The pH transition observed seems to be controlled
by two pKas in the acidic (pKa = 6.7 ± 0.08) and basic pH
range: (pKa = 7.3 ± 0.06). The Vmax-pH proﬁle yields the
pKa, which reﬂects the ionization of the enzyme in complex
withsubstrate[29].AsthereisnoionizablegroupsonSDSin
the pH range 5.9–8.5, one can conclude that these pKasm u s t
be for an enzyme side chains.
3.2. Eﬀect of SDS and NADPH Concentration on the Enzyme
Activity. The steady-state kinetics for CYP102A2 was deter-
mined by monitoring the SDS dependent oxidation of
NADPH. The eﬀect of SDS and NADPH concentration on
the reaction rate was studied at 37
◦C as shown in Figure 2
and the results are listed in Table 1. The dependence of reac-
tion rate on NADPH and SDS concentration was hyperbolic
and nonhyperbolic, respectively. Nonhyperbolic data sets
showed sigmoidal characteristics and were accurately ﬁtted
by the Hill function. Similar nonhyperbolic kinetics was also
observed using lauric acid as substrate (Table 1).
The actual role of nonhyperbolic dependence is not
understood. However, it appears more likely that several
structural changes throughout the extended hydrophobic
active sites in the heme domain of CYP102A2 combine to
alter the substrate binding modes in this enzyme and to
produce the apparent nonhyperbolic dependence of kinetic
on the substrate concentration [5]. Alternatively, the non-
hyperbolic dependence probably indicates that CYP102A2
is able to bind simultaneously more molecules of SDS
substrates. This which probably shows that the binding4 Enzyme Research
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Figure 3: Amino acid sequence alignments. Sequence alignments of heme domain of CYP102A1 (residues 1–472) of B. megaterium
ﬂavocytochrome P450 BM3 (NCBI accession number A34286) with the respective domain of CYP102A2 from B. subtilis (NCBI accession
number O08394). The alignments were produced using Clustal W [25] and visualied using ESPript [26]. The secondary structure of
CYP102A1 (pdb 1FAG) and numbering are shown above the alignment. Alpha helices and beta strands are represented as helices and
arrows, respectively, and beta turns are marked with TT. Conserved areas are shown shaded. A column is framed, if more than 70% of its
residues are similar according to physicochemical properties.
process reﬂects cooperative binding of more than one
SDS molecule to the active sites of this enzyme. Atypical
(non-Michaelis-Menten) kinetic features have also been
observed for several drug metabolising enzyme such as
CYP3A4 [5]. In the case of CYP3A4 it has been sug-
gested that this atypical kinetics is due to the existence
of, and interaction between, several binding sites on the
enzyme. The large CYP3A4 active site may allow the
simultaneous presence of multiple molecules and the exact
binding conformations appear to depend on the substrates
involved, their relative concentration, and aﬃnity for the
enzyme.
CYP102A2 exhibits higher Km values compared to
CYP102A1 towards identical substrates. [23]. Comparing
both the amino acid sequences of CYP102A1 and CYP102A2
(Figure 3) and their structures showed signiﬁcant diﬀerences
within the substrate access channel, which might explain
the diﬀerent kinetic constants found for CYP102A2. For
example, the fatty acid substrate in the crystal structure of
CYP102A1 [3] exhibits total 29 interactions. On the other
hand the fatty acid substrate in the modeled structure of
CYP102A1exhibitsfewerinteractions(total22interactions).
Arg47 and Tyr51 (Figure 3) in CYP102A1 is of particular
importance since it is located at the entrance of the activeEnzyme Research 5
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Figure 4: Kinetic analysis of CYP102A2. Initial velocity analysis of CYP102A2 with NADPH as the variable substrate for several ﬁxed
concentrations of SDS (mM): 0.7, ( ); 1 mM, (•); 2 mM, ().
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Figure 5: SDS binding to CYP102A2. (a) The spectral changes induced on titration of CYP102A2 with SDS are shown. Arrows indicate
directions of change of spectra induced by successive additions of SDS. Diﬀerence spectral titrations of CYP102A2 (curve a) and the
CYP102A2-SDS 0.8653mM (curve b) and CYP102A2-SDS 1.726mM (curve c) and CYP102A2-SDS 2.1553mM (curve d) complexes. (b)
The diﬀerence absorbance at 420nm as a function of the total SDS concentration.
site and interacts with the carboxylate group of the fatty
acid substrate [3]. These residues are considered crucial
for the proper positioning of the substrate [31, 32]. In
CYP102A2, residue 48 (homologous to Arg47 in CYP102A1)
is Gly (Figure 3), which rules out a direct eﬀect on substrate
binding. In addition, residue 51 (homologous to Tyr51) is
Val in our homology model of CYP102A2. Its side-chain is
∼6.5 ˚ A away from the substrate which suggests that Val51
might not interact directly with the substrates. Instead of
Arg47, Arg353 might interact directly with the carboxylate
group of the fatty acid substrate, although the distance
between these groups is rather long (∼7 ˚ A).
CYP102A2 undergoes inhibition by NADPH at concen-
trations above 0.1mM. The apparent Michaelis constant is
shown in Table 1. When NADPH was the variable substrate
with several ﬁxed concentrations of SDS, an intersecting pat-
tern of Lineweaver-Burk plot was obtained (Figure 4). When
theslopesandtheinterceptsoftheprimaryLineweaver-Burk
plots were replotted against the reciprocals of the second
ﬁxed substrate, a linear relationship was obtained. Product
inhibition studies were conducted with both NADP+ and
NAD+. With NADPH as the variable substrate, NADP+ and
NAD+ gave linear competitive inhibition with Ki equal to
0.1mM and 149.5mM, respectively. The intersecting initial
velocity pattern obtained and the competitive inhibition
obtained using NADP+ and NAD+ are all consisted with a
rapid-equilibrium ordered bi-bi kinetic mechanism.
3.3. Spectral Binding Titrations. The tight binding of various
long chain saturated and unsaturated fatty acids to P450
BM3 has been demonstrated by several groups [13, 23, 31,
32]. Binding of fatty acids to P450 BM3 induces a shift in
equilibrium of the heme iron spin state toward the high-
spin form, leading to changes in the absorption spectrum
in the Soret region [23]. To analyse the binding of SDS
to CYP102A2, diﬀerence spectral titrations were performed.
Figure 5(a) illustrates the spectral perturbations observed
for CYP102A2 on titration with SDS. SDS binding showed6 Enzyme Research
Table 1: Kinetic parameters of CYP102A2 using SDS and NADPH
as substrates. Steady-state kinetic measurements were performed at
37
◦C in 0.1M potassium phosphate buﬀer, pH 7.2. All initial veloc-
ities were determined in triplicate. The kinetic parameters Kcat and
Km for NADPH were calculated by nonlinear regression analysis of
experimental steady-state data using the GraFit (Erithacus Software
Ltd.) program. The Vmax value, S0.5, and the Hill coeﬃcient, nH,
for SDS were determined by ﬁtting the plotted vversus substrate
concentration to the Hill equation using the GraFit (Erithacus
Software Ltd.) program.
NADPH
kcat (s−1) Km(μM) Kcat/Km (μM
−1 ∗s−1)
2.05 ±0.05 8.30 ±0.62 0.25
SDS
S0.5 (mM) Vmax (μmol/min) nH
1.22 ±0.04 0.18 ±0.0111 5.7 ±0.66
Lauric acid
S0.5 (mM) Vmax (μmol/min) nH
0.47 ±0.005 0.088 ±0.003 8.7 ±0.57
perturbation of the heme spectrum of CYP102A2, with shift
of the resting (substrate free, low-spin) Soret band from
418 nm toward a new position (at 390nm), typical of the
high-spin forms. Gustafsson et al. [23], have reported that
comparison of the extent of spin-state perturbation induced
between SDS and other fatty acids shows a signiﬁcant
variation. Far more extensive shifts in spin-state equilibrium
are observed for the unsaturated and branched-chain fatty
acids than with the SDS.
Plot of the absorption change versus SDS concentration
(Figure 5(b)) was ﬁtted accurately to the Hill function,
which probably indicates that the binding process reﬂects
cooperative binding of more than one SDS molecule to the
active sites of the enzymes. This ﬁnding further supports the
results observed by kinetic analysis.
In conclusion, in this report we addressed questions
regarding the kinetic properties of CYP102A2, a poorly
characterized enzyme among the CYP. Detailed studies of
bacterial CYPs are justiﬁed because of the considerable
biotechnological potential of these enzymes. Further inves-
tigations of this interesting P450 monooxygenase are now in
progress in this laboratory. This includes the isolation and
characterization of mutants, obtained by in vitro directed
evolution.
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4. AbbreviationsUsed
BMP, the heme domain of P450 BM3; CPR, NADPH: cyto-
chrome P450 reductase; CYP, cytochrome P450; CYP102A1
or CYP102 or P450 BM3, cytochrome P450 monooxygenase
from Bacillus megaterium; CYP102A2, cytochrome P450
monooxygenase from Bacillus subtilis;F A D ,ﬂ a v i na d e -
nine dinucleotide; FMN, ﬂavin mononucleotide; NADP+,
β-nicotinamide-adenine dinucleotide phosphate; NADPH,
β-nicotinamide-adenine dinucleotide phosphate, reduced
form; pCYP102A2, the expression vector pCR T7/CT-TOPO
which contains the gene of CYP102A2; SDS, sodium dodecyl
sulphate.
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